VELETRI® (epoprostenol)
Sensitivity of VELETRI to Light in an Extension Line

CLINICAL DATA

In a study that was performed to measure the stability of VELETRI for injection at different temperatures following dilution to various concentrations of epoprostenol, experimental samples were not shielded from light.[1]

Additionally, during the studies EPITOME-1[2] and EPITOME-2[3] comparing the administration of epoprostenol sodium for injection (e.g., Flolan®) and VELETRI for injection in patients with PAH, light-sensitive lines were not used.[2-4]

Direct exposure to sunlight may lead to warming of the VELETRI for injection solution and consequently, a negative impact on product potency. For this reason, VELETRI for injection solutions should be shielded from direct sunlight.[5]

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) was conducted on 27 March 2024.

REFERENCES

1. Lambert O, Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. *Drug Des Devel Ther*. 2012;6((Suppl. 23049244)):235-244.

2. Chin KM, Badesch DB, Robbins IM, et al. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. *Am Heart J*. 2014;167(2):218-225.e1.

3. Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. *Am Heart J*. 2014;167(2):210-217.

4. Data on File. Epoprostenol. AC-066A401/402 Clinical Study Report (EPITOME-1) and AC-066A301 Clinical Study Report (EPITOME-2). Janssen Scientific Affairs, LLC; 2021.

5. Epoprostenol. Company Core Data Sheet. Janssen Scientific Affairs, LLC. EDMS-ERI-205912254. 2021.